ViGenCell Inc. is a healthcare and biotechnology research firm based in Seoul, South Korea. Founded in 1995, the company employs 101-500 people. ViGenCell's immune cell therapy technology has been clinically proven effective through research conducted at the Catholic University of Korea, College of Medicine. The company has received investments from domestic pharmaceutical and venture capital sources. ViGenCell is listed on KOSDAQ and specializes in immune cell therapy. Their platform technologies include ViTier™, ViMedier™, and ViRanger™, which focus on antigen-specific killer T cell therapy, cord blood-derived myeloid suppressor cell therapy, and "off-the-shelf" allogenic universal T cell gene therapy, respectively. By developing precision medical diagnosis products, ViGenCell aims to improve the life extension and quality of life for patients with disorders and malignant diseases. They are dedicated to developing immune cell therapies based on their three platform technologies.
Headquarters
Banpo-Daero 222, Seocho-Gu
Seoul; Seoul;
Contact Details: Purchase the Vigencell Inc. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service